EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN–DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES
A Nookaa, A Lesokhinb, M Mohtyc, R Niesvizkyd, C Maisele, B Arnulff, S Larsong, A Varshavsky-Yanovskyh, X Leleui, L Karlinj, D Vesolek, N Bahlisl, CF Larream, N Rajen, E Leipo, U Contep, M Elmeliegyq, A Viqueirar, V Blunks, S Maniert
a Winship Cancer Institute, Atlanta, United States
b Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College, New York, United States
c Sorbonne University, Hôpital Saint-Antoine, and INSERM UMRs938, Paris, France
d Weill Cornell Medical College – New York Presbyterian Hospital, New York, United States
e Baylor University Medical Center, Dallas, United States
f Hôpital Saint-Louis, Paris, France
g University of California Los Angeles Medical Center, Los Angeles, United States
h Fox Chase Cancer Center, Philadelphia, United States
i Centre Hospitalier Universitaire de Poitiers, Poitiers, France
j Centre Hospitalier Lyon, Lyon, France
k John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, United States
l Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada
m Hospital Clinic de Barcelona, Barcelona, Spain
n Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, United States
o Pfizer Inc, Cambridge, United States
p Pfizer Inc, New York, United States
q Pfizer Inc, San Diego, United States
r Pfizer SLU, Madrid, Spain
s Pfizer, São Paulo, Brazil
t Lille University Hospital, Lille, France
Ver másRead
279
Timeswas read the article
130
Total PDF
149
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 May | 35 | 24 | 59 |
| 2024 April | 45 | 19 | 64 |
| 2024 March | 28 | 15 | 43 |
| 2024 February | 11 | 15 | 26 |
| 2024 January | 11 | 8 | 19 |
| 2023 December | 6 | 17 | 23 |
| 2023 November | 8 | 22 | 30 |
| 2023 October | 5 | 10 | 15 |
